CIK 0000899923
- Accelerated filer
MYRIAD GENETICS INC
Sign in to watch- Ticker
- MYGN
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 870494517
- Phone
- +1 801-584-3600
- Business address
- 322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
- Former names
- MYRIAD GENETICS INC
- 4 Grant or award President and CEO acquired 197,023 shares (grant or award)
- 4 Grant or award Chief Scientific Officer acquired 28,459 shares (grant or award)
- 4 Grant or award Chief Technology Officer acquired 28,459 shares (grant or award)
- 4 Grant or award Chief Accounting Officer acquired 6,000 shares (grant or award)
- 4 Grant or award Chief Commercial Officer acquired 39,405 shares (grant or award)
- 4 Open-market sale Chief Financial Officer sold 15,000 shares at $22.55 ($338,253)
- 4 Open-market sale Chief Operating Officer sold 13,184 shares at $22.74 ($299,823)
- 4 Grant or award Chief People Officer acquired 15,856 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Insider Changes in Ownership
- 4 Shares withheld for taxes SVP, Chief of Staff gave up 2,556 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Technology Officer gave up 1,012 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Financial Officer gave up 11,222 shares (to pay taxes)
- 4 Open-market sale Chief Financial Officer sold 9,400 shares at $20.04 ($188,386)
- 4 Open-market sale Chief Financial Officer sold 600 shares at $20.01 ($12,006)
- 4 Shares withheld for taxes Chief Scientific Officer gave up 302 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Operating Officer gave up 853 shares (to pay taxes)
- 4 Open-market sale Chief Financial Officer sold 20,000 shares at $15.15 ($302,992)
- 4 Grant or award Director acquired 16,875 shares (grant or award)
- 3 Insider Initial Statement of Ownership
Page 12 of 65 · 1,293 filings